Giacca M, Zanussi S, Comar M, Simonelli C, Vaccher E, de Paoli P, Tirelli U
International Centre for Genetic Engineering and Biotechnology, Trieste, Italy.
J Infect Dis. 1996 Jul;174(1):204-9. doi: 10.1093/infdis/174.1.204.
To assess the efficacy of the therapeutic use of inhibitors of ribonucleotide reductase for the treatment of human immunodeficiency virus (HIV) type 1 infection, 7 consecutive patients were enrolled in a clinical trial involving monotherapy with hydroxyurea for 8-19 weeks. During therapy, patients were evaluated for clinical status and immunologic, hematologic, and quantitative virologic parameters, including determinations of viremia and the number of provirus-containing cells by competitive polymerase chain reaction. In all patients, these parameters were not modified during the course of therapy. The number of CD4 cells remained generally unchanged or showed a tendency to further decline. No sign of improvement in HIV disease was detected in any patient. These observations indicate that monotherapy with hydroxyurea does not provide therapeutic benefit to HIV-1-infected patients.
为评估核糖核苷酸还原酶抑制剂用于治疗1型人类免疫缺陷病毒（HIV）感染的疗效，7例连续患者参加了一项临床试验，该试验涉及羟基脲单药治疗8至19周。治疗期间，对患者的临床状况、免疫、血液学和定量病毒学参数进行评估，包括通过竞争性聚合酶链反应测定病毒血症和含前病毒细胞的数量。在所有患者中，这些参数在治疗过程中均未改变。CD4细胞数量总体保持不变或有进一步下降的趋势。未在任何患者中检测到HIV疾病改善的迹象。这些观察结果表明，羟基脲单药治疗对HIV-1感染患者无治疗益处。
